Pharmacologic profiles of GA0113, a novel quinoline derivative angiotensin II AT1-receptor antagonist

Journal of Cardiovascular Pharmacology

Volumn 34, Issue 4, 1999, Pages 526-532

  Ebisu, Hajime ^a   Nishikawa, Masakuni ^a   Tanaka, Mikio ^a   Okazoe, Takashi ^b   Morizawa, Yoshitomi ^b   Shinyama, Hiroshi ^a   Nakamura, Norifumi ^a  

^a Yoshitomi Pharmaceutical Industries Ltd   (Japan)

^b ASAHI GLASS CO LTD   (Japan)

Author keywords

Angiotensin II; Antihypertensive agent; AT1 receptor antagonist; GA0113; Hypertension; Rat

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR; ANTIHYPERTENSIVE AGENT; CANDESARTAN HEXETIL; GA 0113; LOSARTAN POTASSIUM; QUINOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG STRUCTURE; HYPERTENSION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RABBIT; RECEPTOR BINDING; VASOCONSTRICTION;

ANIMALS; BINDING, COMPETITIVE; BIOLOGICAL AVAILABILITY; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART RATE; MALE; PROTEIN BINDING; QUINOLINES; RABBITS; RADIOLIGAND ASSAY; RATS; RATS, INBRED SHR; RATS, WISTAR; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, ANGIOTENSIN; SULFONAMIDES; TIME FACTORS; VASOCONSTRICTOR AGENTS;

EID: 0032880241     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199910000-00008     Document Type: Article

References (22)

1. Timmermans PB, Wong PC, Chiu AT, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993; 45:205-51.
2. Hodges JH, Hamby JM, Blankley CJ. Angiotensin II receptor binding inhibitors. Drugs Future 1992;17:575-93.
3. Ashton WT. Nonpeptide angiotensin II receptor antagonists. Exp Opin Invest Drugs 1994;3:1105-42.
4. Lo MW, Goldberg MR, McCrea JB, Lu H, Furtek CI, Bjornsson TD. Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin Pharmacol Ther 1995;58:641-9.
5. Kohara Y, Kubo K, Imamiya E, Wada Y, Naka T. Synthesis and angiotensin II receptor antagonistic activities of benzimidazole derivatives bearing acidic heterocycles as novel tetrazole bioisosteres. J Med Chem 1996;39:5228-35.
6. Deprez P, Guillaume J, Becker R, et al. Sulfonylureas and sulfonylcarbamates as new non-tetrazole angiotensin II receptor antagonists: discovery of a highly potent orally active (imidazolylbiphenyl) sulfonylurea (HR720). J Med Chem 1995;38:2357-77.
7. 1) receptor antagonist. Drug Dev Res 1994;32:161-71.
8. Scatchard G. The attraction of protein for small molecules and ions. Ann N Y Acad Sci 1949;51:660-72.
9. Ariens EJ, van Rossum JM. pDx, pAx and pD*x values in the analysis of pharmacodynamics. Arch Int Pharmacodyn 1957;10: 275-99.
10. 1 receptor. Eur J Pharmacol 1997;319:137-46.
11. Cangiano JL, Rodriguez-Sargent C, Martinez-Maldonado M. Effects of antihypertensive treatment on systolic blood pressure and renin in experimental hypertension in rats. J Pharmacol Exp Ther 1979;208:310-3.
12. Goldberg MR, Bradstreet TE, McWilliams EJ, et al. Biochemical effects of losartan: a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients. Hypertension 1995;25:37-46.
13. 1 receptor antagonist irbesartan in hypertension. Hypertension 1995;25:22-9.
14. Delacretaz E, Nussberger J, Biollaz J, Waeber B, Brunner HR. Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers. Hypertension 1995;25:14-21.
15. Wong PC, Barnes TB, Chiu AT, et al. Losartan (DuP 753): an orally active nonpeptide angiotensin II receptor antagonist. Cardiovasc Drug Rev 1991;9:317-39.
16. Hashimoto Y, Harada Y, Narita H, Naito K, Murata S. The pharmacologic profile of 606A: a novel angiotensin II receptor antagonist. J Cardiovasc Pharmacol 1997;29:284-90.
17. Tamura K, Okuhira M, Amano H, et al. Pharmacologic profiles of KRH-594: a novel nonpeptide angiotensin II-receptor antagonist. J Cardiovasc Pharmacol 1997;30:607-15.
18. Nagura J, Yasuda S, Fujishima K, et al. Pharmacological profile of ME3221: a novel angiotensin II receptor antagonist. Eur J Pharmacol 1995;274:201-11.
19. Kondo T, Hagihara K, Kato Y, et al. Metabolic fate of TCV-116: a new angiotensin II receptor antagonist, in rats and dogs. Jpn Pharmacol Ther 1996;24:S-915-42.
20. Elliott HL. Trough/peak ratio and twenty-four-hour blood pressure control. J Hypertens 1994;12:S29-33.
21. Lipicky RJ. Trough/peak ratio: the rationale behind the United States Food and Drug Administration recommendations. J Hypertens 1994;12:517-8.
22. Wada T, Sanada T, Ojima M, Kanagawa R, Nishikawa K, Inada Y. Combined effects of the angiotensin II antagonist candesartan cilexetil (TCV-116) and other classes of antihypertensive drugs in spontaneously hypertensive rats. Hypertens Res 1996;19:247-54.